"Laboratory tests are medically indispensable, but the development, production and provision of the necessary laboratory diagnostics by the industry is costly," says VDGH Managing Director Dr. Martin Walger. "The situation is the same in the medical laboratory and in the industry. Increased material and energy prices, personnel costs and stricter regulatory requirements are having an impact in both areas. This development must not be ignored in the further development of the GOÄ."
The VDGH also points out that many laboratory diagnostic procedures have changed fundamentally since the introduction of the current GOÄ. Although modern technologies such as molecular genetic tests or automated analysis systems enable highly precise diagnoses, they also place new demands on the infrastructure and specialist staff. A proper and appropriate assessment in medical remuneration must take this into account.
The laboratory reform at the beginning of 2025 had already led to considerable cuts in the remuneration of SHI-accredited physicians, despite documented cost increases on the part of the industry and service providers. Against this backdrop, the VDGH emphasizes the need to avoid placing an additional burden on existing care structures. Further talks between the German Medical Association and the specialist groups from the laboratory are expressly welcomed by the diagnostics manufacturers.
"The GOÄ is a central instrument for ensuring quality in private healthcare. A differentiated and future-oriented evaluation of laboratory services is in the interest of all parties involved: from the insured to the industry," says Walger.
